Overview

Combination of Anti-PD-1 and NK Immunotherapy for Recurrent Solid Tumors

Status:
Completed
Trial end date:
2019-07-01
Target enrollment:
Participant gender:
Summary
The aim of this study is the safety and efficacy of anti-PD-1 plus NK immunotherapy to multiple solid tumors.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Fuda Cancer Hospital, Guangzhou
Collaborator:
Shenzhen Hank Bioengineering Institute
Treatments:
Antibodies, Monoclonal
Nivolumab
Pembrolizumab